Microbot Med Inc Financials
This page shows Microbot Med Inc (MBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Microbot is operating as a capital-funded development company, with new financing supporting burn and balance-sheet growth rather than customer-funded operations.
The stronger-looking FY2025 balance sheet did not come from the business turning cash generative:$86.2M of financing flowed in, and$72.4M went back out through investing. So the jump in assets and equity mostly reflects capital being raised and redeployed, while the operating engine still consumed about$13.0M of cash during the year and ended with only$3.9M on hand.
Losses are converting into cash burn with very little accounting distortion or capital-spending noise: net loss was
The spending mix shifted away from a research-led profile: SG&A reached
Financial Health Signals
We are recalculating Microbot Med Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Microbot Med Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Microbot Med Inc reported a net loss of $13.1M while operations used $13.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Microbot Med Inc's EBITDA was -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.4% from the prior year.
Microbot Med Inc reported -$13.1M in net income in fiscal year 2025. This represents a decrease of 14.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Microbot Med Inc recorded an outflow of $13.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 48.1% from the prior year.
Microbot Med Inc held $3.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Microbot Med Inc's ROE was -17.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 307.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Microbot Med Inc invested $6.3M in research and development in fiscal year 2025. This represents a decrease of 5.2% from the prior year.
Microbot Med Inc invested $60K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 140.0% from the prior year.
Not reported for fiscal year 2025.
MBOT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $117K-88.5% | $1.0M+1.4% | $998K-27.0% | $1.4M+12.1% | $1.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $317K+20.3% | $263K+22.5% | $215K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $887K-19.7% | $1.1M+9.8% | $1.0M |
| R&D Expenses | N/A | $6.3M-5.2% | $6.6M+15.8% | $5.7M-26.0% | $7.7M+25.7% | $6.2M+81.2% | $3.4M+11.4% | $3.0M+21.2% | $2.5M+128.6% | $1.1M+22.1% | -$901K+9.5% | -$823K-1.6% | $837K-95.7% | $19.4M+31.9% | $14.7M-26.4% | $19.9M |
| SG&A Expenses | N/A | $8.5M+69.4% | $5.0M+20.9% | $4.1M-25.5% | $5.5M+6.6% | $5.2M-8.6% | $5.7M+35.8% | $4.2M-11.4% | $4.7M+13.5% | $4.2M+147.7% | -$8.7M-9393.5% | -$92K | N/A | $8.8M+20.0% | $7.4M-10.3% | $8.2M |
| Operating Income | N/A | -$14.7M-26.8% | -$11.6M-18.0% | -$9.9M+25.8% | -$13.3M-16.9% | -$11.4M-25.0% | -$9.1M-25.5% | -$7.2M+0.1% | -$7.2M-237.5% | $5.3M+154.7% | -$9.6M-1153.0% | $915K+184.1% | -$1.1M+96.1% | -$28.1M-28.2% | -$21.9M+22.0% | -$28.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2K-99.2% | $237K-28.8% | $333K+5450.0% | $6K-99.5% | $1.3M+11.0% | $1.2M+2224.6% | $50K-29.7% | $71K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$13.1M-14.8% | -$11.4M-6.5% | -$10.7M+18.4% | -$13.2M-16.4% | -$11.3M-23.4% | -$9.2M-26.5% | -$7.2M+0.2% | -$7.3M+4.3% | -$7.6M+21.5% | -$9.7M-949.2% | -$921K+23.7% | -$1.2M+95.4% | -$26.4M+7.2% | -$28.5M-33.6% | -$21.3M |
| EPS (Diluted) | — | -$0.29 | -$0.73 | -$1.05+42.0% | -$1.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MBOT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $81.5M+1252.1% | $6.0M-27.6% | $8.3M-12.7% | $9.5M-43.1% | $16.8M-36.2% | $26.3M-29.2% | $37.1M+509.6% | $6.1M-44.7% | $11.0M+227.2% | $3.4M+536.7% | $529K-44.8% | $958K-97.7% | $41.6M+37.7% | $30.2M+19.7% | $25.2M |
| Current Assets | $79.8M+1271.7% | $5.8M-26.5% | $7.9M-10.1% | $8.8M-44.5% | $15.9M-37.1% | $25.3M-29.7% | $35.9M+516.3% | $5.8M-46.7% | $10.9M+229.7% | $3.3M+575.2% | $491K-45.7% | $904K-97.2% | $31.8M+32.4% | $24.0M+38.3% | $17.4M |
| Cash & Equivalents | $3.9M+25.6% | $3.1M+26.2% | $2.5M+1.1% | $2.4M-81.9% | $13.5M-31.3% | $19.6M-31.7% | $28.8M+449.3% | $5.2M-51.4% | $10.8M+298.2% | $2.7M+519.9% | $437K-44.8% | $791K+120.6% | $359K-95.8% | $8.5M-36.4% | $13.3M |
| Inventory | $584K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $159K+46.5% | $109K-1.2% | $110K+102.0% | $55K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.1M+7.9% | $2.0M+4.7% | $1.9M |
| Total Liabilities | $4.0M+59.5% | $2.5M-34.6% | $3.8M+70.2% | $2.2M-5.8% | $2.4M+21.1% | $2.0M-64.7% | $5.6M+17.4% | $4.8M+756.1% | $556K-52.6% | $1.2M+97.6% | $593K+488.0% | $101K-99.8% | $41.2M+154.4% | $16.2M+11.8% | $14.5M |
| Current Liabilities | $3.4M+39.1% | $2.5M-35.0% | $3.8M+83.0% | $2.1M+4.3% | $2.0M+47.5% | $1.3M-72.1% | $4.8M+1.4% | $4.8M+801.5% | $528K-32.6% | $783K+350.0% | $174K+71.8% | $101K-98.9% | $9.1M+79.2% | $5.1M-9.8% | $5.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $125K-62.3% | $331K |
| Total Equity | $77.6M+2097.0% | $3.5M-21.6% | $4.5M-38.2% | $7.3M-49.3% | $14.4M-40.8% | $24.3M-22.9% | $31.5M+2271.4% | $1.3M-86.7% | $10.0M+489.2% | $1.7M+2750.0% | -$64K-107.5% | $857K+128.7% | $375K-97.3% | $14.0M+30.4% | $10.7M |
| Retained Earnings | -$104.1M-14.5% | -$90.9M-14.4% | -$79.5M-15.6% | -$68.8M-23.7% | -$55.6M-25.5% | -$44.3M-26.1% | -$35.1M-26.0% | -$27.9M-35.1% | -$20.6M-58.2% | -$13.0M-286.6% | -$3.4M-37.6% | -$2.5M+99.4% | -$387.5M-7.3% | -$361.1M-8.6% | -$332.6M |
MBOT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.6M | -$13.0M-47.8% | -$8.8M-3.4% | -$8.5M+26.1% | -$11.5M-23.5% | -$9.4M-29.0% | -$7.3M-12.4% | -$6.5M-21.5% | -$5.3M-9.3% | -$4.9M-517.8% | -$786K-2.7% | -$765K | N/A | -$23.3M-17.4% | -$19.9M+9.9% | -$22.1M |
| Capital Expenditures | $288K | $60K+140.0% | $25K-24.2% | $33K-60.7% | $84K+21.7% | $69K-24.2% | $91K-57.9% | $216K-3.1% | $223K+284.5% | $58K+132.0% | $25K+1150.0% | $2K-82.5% | $11K-99.8% | $4.7M+6304.8% | $73K-75.4% | $297K |
| Free Cash Flow | -$17.9M | -$13.1M-48.1% | -$8.9M-3.3% | -$8.6M+26.4% | -$11.6M-23.5% | -$9.4M-28.3% | -$7.3M-10.1% | -$6.7M-20.5% | -$5.5M-12.6% | -$4.9M-505.9% | -$811K-5.7% | -$767K | N/A | -$28.0M-40.4% | -$19.9M+10.8% | -$22.4M |
| Investing Cash Flow | -$36.8M | -$72.4M-4809.4% | $1.5M-22.1% | $2.0M+151.4% | -$3.8M-219.9% | $3.2M+215.6% | -$2.8M-12.8% | -$2.5M-1000.0% | -$223K-284.5% | -$58K-132.0% | -$25K-1150.0% | -$2K+99.5% | -$426K-104.7% | $9.0M+184.5% | -$10.7M-212.4% | -$3.4M |
| Financing Cash Flow | N/A | $86.2M+986.7% | $7.9M+21.0% | $6.6M+51.7% | $4.3M | N/A | -$3.4M-109.2% | $36.8M+204377.8% | -$18K-100.1% | $13.0M+322.3% | $3.1M+646.5% | $413K | N/A | $36.4M+41.4% | $25.7M+34.5% | $19.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MBOT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 88.8%+8.1pp | 80.8%-1.6pp | 82.4% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 782.8% | -107.5% | -2815.0% | -1601.5% | -2300.1% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -787.9% | -119.2% | -2649.3% | -2082.8% | -1747.3% |
| Return on Equity | -17.0%+307.2pp | -324.2%-85.6pp | -238.6%-57.9pp | -180.7%-102.0pp | -78.7%-40.9pp | -37.7%-14.7pp | -23.0%+522.9pp | -545.9%-469.9pp | -75.9%+493.8pp | -569.8% | N/A | -140.8%+6916.2pp | -7057.0%-6853.2pp | -203.7%-4.9pp | -198.9% |
| Return on Assets | -16.1%+173.6pp | -189.7%-60.8pp | -129.0%+9.1pp | -138.1%-70.6pp | -67.5%-32.6pp | -34.9%-15.4pp | -19.5%+99.7pp | -119.2%-50.3pp | -68.9%+218.0pp | -286.9%-112.8pp | -174.1%-48.1pp | -126.0%-62.4pp | -63.6%+30.8pp | -94.4%-9.8pp | -84.6% |
| Current Ratio | 23.33+21.0x | 2.37+0.3x | 2.09-2.2x | 4.26-3.7x | 8.00-10.8x | 18.78+11.3x | 7.45+6.2x | 1.23-19.5x | 20.70+16.5x | 4.23+1.4x | 2.82-6.1x | 8.93+5.4x | 3.49-1.2x | 4.72+1.6x | 3.08 |
| Debt-to-Equity | 0.05-0.7x | 0.71-0.1x | 0.85+0.5x | 0.31+0.1x | 0.17+0.1x | 0.08-0.1x | 0.18-3.4x | 3.58+3.5x | 0.06-0.6x | 0.69 | N/A | 0.12-109.8x | 109.92+109.9x | 0.010.0x | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -656.2% | N/A | -2806.0% | -1457.8% | -1831.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Microbot Med Inc Ranks
Frequently Asked Questions
Is Microbot Med Inc profitable?
No, Microbot Med Inc (MBOT) reported a net income of -$13.1M in fiscal year 2025.
What is Microbot Med Inc's EBITDA?
Microbot Med Inc (MBOT) had EBITDA of -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Microbot Med Inc's return on equity (ROE)?
Microbot Med Inc (MBOT) has a return on equity of -17.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Microbot Med Inc's free cash flow?
Microbot Med Inc (MBOT) recorded an outflow of $13.1M in free cash flow during fiscal year 2025. This represents a -48.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Microbot Med Inc's operating cash flow?
Microbot Med Inc (MBOT) recorded an outflow of $13.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Microbot Med Inc's total assets?
Microbot Med Inc (MBOT) had $81.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Microbot Med Inc's capital expenditures?
Microbot Med Inc (MBOT) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Microbot Med Inc spend on research and development?
Microbot Med Inc (MBOT) invested $6.3M in research and development during fiscal year 2025.
What is Microbot Med Inc's current ratio?
Microbot Med Inc (MBOT) had a current ratio of 23.33 as of fiscal year 2025, which is generally considered healthy.
What is Microbot Med Inc's debt-to-equity ratio?
Microbot Med Inc (MBOT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Microbot Med Inc's return on assets (ROA)?
Microbot Med Inc (MBOT) had a return on assets of -16.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Microbot Med Inc's cash runway?
Based on fiscal year 2025 data, Microbot Med Inc (MBOT) had $3.9M in cash against an annual operating cash burn of $13.0M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Microbot Med Inc's Piotroski F-Score?
Microbot Med Inc (MBOT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Microbot Med Inc's earnings high quality?
Microbot Med Inc (MBOT) reported a net loss of $13.1M while operations used $13.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.